Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oleoylethanolamide
- Development stage
- Phase 2
- Lead developer
- Innovastics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oleoylethanolamide (OEA) is a naturally occurring ethanolamide lipid and an endogenous peroxisome proliferator-activated receptor alpha (PPAR-α) agonist. It is a monounsaturated analogue of the endocannabinoid anandamide but acts independently of the cannabinoid pathway. OEA regulates feeding behavior and body weight by stimulating satiety, promoting lipolysis, and reducing food intake. Its mechanism involves activation of PPAR-α as well as interaction with GPR119 and transient receptor potential vanilloid type 1 (TRPV1). OEA also exhibits neuroprotective, anti-inflammatory, antioxidant, and analgesic properties. It has been studied primarily for its potential in obesity management but also shows promise in neuroprotection and metabolic regulation[1][2][4][5][6].
- Other names
- oleic monoethanolamideN-oleoylethanolamine
02
Targets
GPR55 (G protein-coupled receptor 55)GPR119 (Glucose-dependent insulinotropic receptor)HIF3A (Hypoxia-inducible factor 3-alpha)PPARA (Peroxisome proliferator-activated receptor alpha)TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Oleoylethanolamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oleoylethanolamide.